Trial Profile
A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec/insulin aspart (Primary) ; Insulin aspart
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 08 Dec 2017 Results comparing the efficacy and safety of insulin degludec/insulin aspart with biphasic insulin aspart 30 during Ramadan, presented at the 2017 Congress of the International Diabetes Federation.
- 07 Dec 2017 According to a Novo Nordisk media release, Dr Mohamed Hassanein of the Dubai Hospital, Dubai Health Authority, UAE and chair of the Diabetes and Ramadan International Alliance (DAR) is the lead investigator of the trial.
- 07 Dec 2017 According to a Novo Nordisk media release, results from the study were presented at the International Diabetes Federation Congress 2017 (IDF 2017).